PDS Biotech shareholders approve doubling authorized shares to 300M; reelect two directors

PDS Biotechnology Corp

Shareholders approved amendment increasing authorized common stock from 150M to 300M shares (19.9M for, 11.5M against).
Kamil Ali-Jackson and Ilian Iliev elected as Class B directors; each received ~9M votes for.
KPMG US LLP ratified as independent auditor for FY2026 (30.4M for).
Non-binding say-on-pay approved (7.2M for, 4.0M against, 19.3M broker non-votes).
Quorum of 56.6% (31.6M of 55.8M shares) represented at meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.